Fatma Gul, MD
Physical Medicine & Rehabilitation · Dallas, TXNPI 1346233517
Payments from drug & device makers
Across 959 payments — averaging $597.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Pharma SAS$262K
- Merz Pharmaceuticals, LLC$163K
- AbbVie$66K
- MDD US Operations, LLC$65K
- Merz North America, Inc.$7K
- Neurocrine Biosciences, Inc.$4K
- plus $6K from 5 others
Across 4 payments — averaging $195.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$782
What the payments were for
- Consulting fees$6,23030%
- Speaking & faculty fees$6,97534%
- Travel & lodging$2,24111%
- Food & beverage$4,71423%
- Education$850%
- Gifts$3152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Pharma SAS | 97 | $261,823 |
| Merz Pharmaceuticals, LLC | 27 | $163,259 |
| AbbVie(2 entities) | 39 | $66,275 |
| MDD US Operations, LLC | 707 | $64,727 |
| Merz North America, Inc. | 25 | $7,059 |
| Neurocrine Biosciences, Inc. | 11 | $4,152 |
| Medtronic(2 entities) | 30 | $2,647 |
| Saol Therapeutics Inc. | 11 | $2,312 |
| Ipsen Biopharmaceuticals, Inc | 9 | $487 |
| Pacira Pharmaceuticals Incorporated | 2 | $160 |
| Tersera Therapeutics LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$11,018
- LIORESAL$2,098
- SYNCHROMED$1,759
- DYSPORT$1,330
- SYNCHROMEDII$252
- XEOMIN$173
How this compares
$572,918 in reported general payments places this provider in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.
See all physical medicine & rehabilitation providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 11 | $8,548 |
| Pregabalin | 32 | $6,483 |
| Baclofen | 97 | $3,449 |
| Glycopyrrolate | 15 | $1,701 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,493 |
| Fentanyl | 11 | $1,223 |
| Gabapentin | 22 | $1,083 |
| Dantrolene Sodium | 24 | $1,015 |
| Morphine Sulfate | 12 | $467 |
| Oxycodone Hcl | 19 | $419 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $389 |
| Tizanidine Hcl | 26 | $291 |
| Hydromorphone Hcl | 11 | $156 |
| Diazepam | 23 | $113 |
| Trazodone Hcl | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Dallas
- Gireesh ShardaDallas$172K
- Surendra BarshikarDallas$135K
- James GarrisonDallas$95K
- Rita HamiltonDallas$64K
- Priya ChittaDallas$15K
- Nikesh PatelDallas$14K
- Rinoo ShahDallas$7K
- Christine VidouriaSan Antonio$841K
- Gerard FranciscoHouston$520K
- Jose UrquidezAustin$332K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.